Monopar Therapeutics (NASDAQ:MNPR) Sets New 1-Year High – Should You Buy?

Monopar Therapeutics Inc. (NASDAQ:MNPR)’s share price reached a new 52-week high during trading on Thursday . The stock traded as high as $120.42 and last traded at $119.8760, with a volume of 5572 shares trading hands. The stock had previously closed at $119.23.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. UBS Group set a $125.00 target price on Monopar Therapeutics in a research note on Thursday, July 23rd. Wall Street Zen raised Monopar Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Piper Sandler set a $105.00 price objective on Monopar Therapeutics in a research report on Tuesday, June 2nd. BTIG Research increased their price objective on Monopar Therapeutics from $104.00 to $117.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Finally, Zacks Research raised Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. Three equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $112.08.

Monopar Therapeutics Stock Down 0.8%

The company’s fifty day moving average price is $90.83 and its 200 day moving average price is $70.05. The company has a market capitalization of $798.71 million, a P/E ratio of -62.74 and a beta of 1.47.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.41. Research analysts predict that Monopar Therapeutics Inc. will post -2.82 earnings per share for the current fiscal year.

Institutional Trading of Monopar Therapeutics

Institutional investors have recently modified their holdings of the stock. ADAR1 Capital Management LLC raised its position in shares of Monopar Therapeutics by 13.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after buying an additional 30,370 shares in the last quarter. Siren L.L.C. boosted its position in shares of Monopar Therapeutics by 27.2% during the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after acquiring an additional 57,820 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Monopar Therapeutics during the 4th quarter worth approximately $654,000. Walleye Capital LLC bought a new position in Monopar Therapeutics in the first quarter valued at approximately $3,458,000. Finally, Bank of New York Mellon Corp raised its position in Monopar Therapeutics by 21.2% during the first quarter. Bank of New York Mellon Corp now owns 78,618 shares of the company’s stock valued at $4,307,000 after purchasing an additional 13,761 shares in the last quarter. 1.83% of the stock is currently owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.